JP5749014B2 - ポリプリントラクト改変レトロウイルスベクター - Google Patents

ポリプリントラクト改変レトロウイルスベクター Download PDF

Info

Publication number
JP5749014B2
JP5749014B2 JP2010538155A JP2010538155A JP5749014B2 JP 5749014 B2 JP5749014 B2 JP 5749014B2 JP 2010538155 A JP2010538155 A JP 2010538155A JP 2010538155 A JP2010538155 A JP 2010538155A JP 5749014 B2 JP5749014 B2 JP 5749014B2
Authority
JP
Japan
Prior art keywords
vector
nucleic acid
sequence
ltr
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010538155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505835A (ja
JP2011505835A5 (enExample
Inventor
カフリ タル
カフリ タル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2011505835A publication Critical patent/JP2011505835A/ja
Publication of JP2011505835A5 publication Critical patent/JP2011505835A5/ja
Application granted granted Critical
Publication of JP5749014B2 publication Critical patent/JP5749014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Artificial Filaments (AREA)
JP2010538155A 2007-12-11 2008-12-11 ポリプリントラクト改変レトロウイルスベクター Expired - Fee Related JP5749014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US711807P 2007-12-11 2007-12-11
US61/007,118 2007-12-11
PCT/US2008/086409 WO2009076524A2 (en) 2007-12-11 2008-12-11 Polypurine tract modified retroviral vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015013974A Division JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Publications (3)

Publication Number Publication Date
JP2011505835A JP2011505835A (ja) 2011-03-03
JP2011505835A5 JP2011505835A5 (enExample) 2012-02-02
JP5749014B2 true JP5749014B2 (ja) 2015-07-15

Family

ID=40756119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010538155A Expired - Fee Related JP5749014B2 (ja) 2007-12-11 2008-12-11 ポリプリントラクト改変レトロウイルスベクター
JP2015013974A Expired - Fee Related JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015013974A Expired - Fee Related JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Country Status (16)

Country Link
US (2) US9796987B2 (enExample)
EP (2) EP3342872A1 (enExample)
JP (2) JP5749014B2 (enExample)
CY (1) CY1119905T1 (enExample)
DK (1) DK2222861T3 (enExample)
ES (1) ES2664988T3 (enExample)
HR (1) HRP20180184T1 (enExample)
HU (1) HUE036103T2 (enExample)
LT (1) LT2222861T (enExample)
NO (1) NO2222861T3 (enExample)
PL (1) PL2222861T3 (enExample)
PT (1) PT2222861T (enExample)
RS (1) RS56844B1 (enExample)
SI (1) SI2222861T1 (enExample)
TR (1) TR201802323T4 (enExample)
WO (1) WO2009076524A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
EP2456786B2 (en) * 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
KR101607282B1 (ko) 2014-12-18 2016-03-29 충남대학교산학협력단 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2017066570A1 (en) * 2015-10-15 2017-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for integration-defective lentiviral vectors
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
EA201890861A1 (ru) 2015-11-09 2018-10-31 Иммьюн Дизайн Корп. Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
KR20180074699A (ko) 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
CN109154005A (zh) 2016-02-23 2019-01-04 免疫设计股份有限公司 多基因组逆转录病毒载体制剂及用于产生及使用该制剂的方法和系统
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
JP7483373B2 (ja) 2016-07-29 2024-05-15 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
EP4549554A3 (en) 2017-07-29 2025-08-06 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
KR102755437B1 (ko) 2017-08-09 2025-01-20 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN111918972A (zh) 2018-01-31 2020-11-10 朱诺治疗学股份有限公司 评估存在或不存在有复制能力的病毒的方法和试剂
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
BR112021020447A2 (pt) 2019-04-17 2022-05-17 Alpine Immune Sciences Inc Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
US20220228101A1 (en) 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
EP4070097A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
US20230071910A1 (en) 2020-01-24 2023-03-09 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
AU2022269139A1 (en) 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
IL319997A (en) 2022-10-04 2025-06-01 Alpine Immune Sciences Inc Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
EP4716851A2 (en) 2023-05-23 2026-04-01 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2024263991A2 (en) * 2023-06-22 2024-12-26 Arc Research Institute Methods and compositions for integration deficient viral vectors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
ATE455858T1 (de) * 1995-11-28 2010-02-15 Univ Johns Hopkins Med Konditionell replizierende virale vektoren und ihre verwendung
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
US6673567B2 (en) 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
WO2002042482A2 (en) * 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
AU2003260769A1 (en) * 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US7220578B2 (en) 2002-11-27 2007-05-22 Tal Kafri Single LTR lentivirus vector
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US20060019393A1 (en) * 2003-12-04 2006-01-26 Cannon Paula M Minimal lentiviral vector system
JP2007054069A (ja) * 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa

Also Published As

Publication number Publication date
JP6001702B2 (ja) 2016-10-05
US20180119170A1 (en) 2018-05-03
SI2222861T1 (en) 2018-04-30
JP2011505835A (ja) 2011-03-03
PT2222861T (pt) 2018-02-16
WO2009076524A3 (en) 2009-09-11
EP2222861A2 (en) 2010-09-01
EP3342872A1 (en) 2018-07-04
DK2222861T3 (en) 2018-02-05
US9796987B2 (en) 2017-10-24
PL2222861T3 (pl) 2018-04-30
JP2015119715A (ja) 2015-07-02
US10017785B2 (en) 2018-07-10
US20100323403A1 (en) 2010-12-23
NO2222861T3 (enExample) 2018-05-05
HUE036103T2 (hu) 2018-06-28
WO2009076524A2 (en) 2009-06-18
HRP20180184T1 (hr) 2018-04-06
CY1119905T1 (el) 2018-06-27
LT2222861T (lt) 2018-03-26
RS56844B1 (sr) 2018-04-30
ES2664988T3 (es) 2018-04-24
EP2222861A4 (en) 2011-12-28
EP2222861B1 (en) 2017-12-06
TR201802323T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
JP6001702B2 (ja) ポリプリントラクト改変レトロウイルスベクター
US10184136B2 (en) Retroviral vectors
KR102091957B1 (ko) 레트로바이러스 생산을 위한 안정한 세포주
US8828718B2 (en) Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
ES2951857T3 (es) Vector retroviral
JP2019500030A (ja) レトロウイルス産生のための一時的トランスフェクション法
KR20220154734A (ko) 렌티바이러스 벡터
JP2023513303A (ja) レンチウイルスベクターの製造
Negre et al. Lentiviral vectors derived from simian immunodeficiency virus
CA2408786C (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
WO2024263991A2 (en) Methods and compositions for integration deficient viral vectors
US20250122528A1 (en) Lentiviral vector
US20230151388A1 (en) Modified vectors for production of retrovirus
van Heuvel Optimization of retroviral packaging cells for scale-up of vector production
WO2025213067A2 (en) Methods and compositions for increased expression of integration deficient viral vectors
Heuvel Optimization of retroviral packaging cells for scale-up of vector production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150513

R150 Certificate of patent or registration of utility model

Ref document number: 5749014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees